Document is current
Any future updates will be listed below
-
Authors
Duan, Hao
Xie, Yuan
Wu, Suwen
Zhao, Guangyin
Zeng, Zhen
Hu, Hongrong
Yu, Yanjiao
Hu, Wanming
Yang, Yuanzhong
Chen, Yukun
Xie, Haoqun
Chen, Zexin
Zhang, Gao
Flaherty, Keith T.
Hu, Shanshan
Xu, Haineng
Ma, Wenjuan
Mou, Yonggao http://orcid.org/0000-0001-6045-503X
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82002628)
Basic and Applied Basic Research Foundation of Guangdong Province (2020A1515110069)
Natural Science Foundation of Sichuan Province (2023NSFSC1884)
Postdoctor Research Fund of West China Hospital, Sichuan University (2023HXBH105)
- License Information
-
More Information
Article History
Received: 14 April 2024
Accepted: 4 September 2024
First Online: 30 September 2024
Declarations
:
: The Medical Ethics Committees of Sun Yat-sen University Cancer Center approved this study (no. B2021-427-01). All procedures performed in this study involving human participants were in accordance with the ethical standards of the Medical Ethics Committees of Sun Yat-sen University Cancer Center, followed the 1964 Helsinki Declaration and its later amendments. Informed consent to review medical data was obtained from all patients.
: Not applicable.
: K.T. Flaherty reports personal fees and other support from Clovis Oncology, Kinnate Biopharma, Checkmate Pharmaceuticals, Strata Oncology, Scorpion Therapeutics, PIC Therapeutics, Apricity, Tvardi, xCures, Monopteros, Vibliome, ALX Oncology, Fog Pharma, and Soley Therapeutics, as well as personal fees from Nextech, Takeda, Transcode Therapeutics, and Novartis during the conduct of the study. No disclosure is reported by the other authors.
